Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01209325
Other study ID # AMC-072
Secondary ID AMC-072U01CA1219
Status Completed
Phase Phase 2
First received
Last updated
Start date June 28, 2011
Est. completion date December 12, 2017

Study information

Verified date August 2020
Source AIDS Malignancy Consortium
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.

PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.


Description:

OBJECTIVES:

Primary

- To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing penile/scrotal condyloma and HPV-6, -11, -16, -18- associated perianal/anal disease in HIV-positive males who have sex with males (MSM) age 13-26 years by comparing the incidence of these lesions among those naïve to the relevant HPV type(s) at baseline to those who are not naïve at baseline.

- To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing persistent anogenital infection with HPV-6, -11, -16, or 18 in HIV-positive MSM age 13-26 years by comparing the incidence of persistent infection among those naïve to the relevant HPV type(s) at baseline to those who are not naïve at baseline.

- To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing anogenital lesions associated with HPV 6,-11,-16, -18 and persistent infection with these types, in HIV-positive MSM age 13-26 years by comparing the incidence of lesions and persistent infection among those naïve to the relevant types at baseline to incident lesions and infection among MSM naïve to these HPV types who participated in the Merck 020 protocol and who received placebo as part of the protocol.

Secondary

- To define the safety of the HPV-6, -11, -16, -18 vaccine in HIV-positive MSM age 13-26 years.

- To evaluate the levels and persistence of HPV 6, 11, 16 and 18 Ab titers after the vaccination series among subjects who are seropositive and seronegative at baseline.

- To examine whether the protective effect and antibody titers vary as a function of the following at the time of initial vaccination: subject age, HAART treatment status, HIV viral load, CD4 + T-cell count, and nadir CD4 level.

Tertiary

- To quantify anogenital HPV DNA viral load prior to and after receipt of the quadrivalent HPV vaccine.

- To identify and quantify HPV types in the oral cavity of HIV-positive MSM prior to and after receipt of the quadrivalent HPV vaccine.

- To identify HPV strain variants among HIV-positive participants prior to and after receipt of the quadrivalent HPV vaccine.

- Assess the prevalence and incidence of urinary and gonorrhea and Chlamydia trachomatis infection at baseline and their relationship with prevalent and incident anogenital HPV infection and anal condyloma or AIN.

- To characterize young men's risk perceptions, sexual behaviors, and STI diagnosis after HPV vaccination.

OUTLINE: This is a multicenter study.

Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine intramuscularly on day 1 and in weeks 8 and 24.

Blood and tissue samples may be collected periodically for laboratory studies.

After completion of study treatment, patients are followed up for 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 149
Est. completion date December 12, 2017
Est. primary completion date December 12, 2017
Accepts healthy volunteers No
Gender Male
Age group 13 Years to 26 Years
Eligibility DISEASE CHARACTERISTICS:

- Men with a history of at least one male sexual partner

- "Men" is defined as those documented "male" at birth (including male-to-female transgendered persons)

- HIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (ELISA, western blot, or other approved test)

- Alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests

- Meets one of the following sets of criteria:

- Patients receiving antiretroviral therapy:

- Receipt of antiretroviral therapy for at least 3 months prior to entry

- No change in antiretroviral therapy within 30 days prior to entry

- Patients not receiving antiretroviral therapy:

- CD4-cell count = 350 cells/mm³ within 90 days prior to study entry

- No plans to start antiretroviral therapy prior to Week 28

- Normal anal cytological result, LSIL/condyloma, or ASCUS result within 90 days prior to entry, and no HGAIN on biopsy

- No current or history of anal or peri-anal carcinoma

- No anal cytological result of HSIL, atypical squamous cells suggestive of HSIL (ASC-H), or suggestive of invasive carcinoma at screening; or history of these results

- No presence of penile or scrotal condyloma, LGAIN (condyloma or AIN 1), HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma at pre-entry on biopsy

- No history of HGAIN

PATIENT CHARACTERISTICS:

- Karnofsky performance score = 70 within 45 days prior to entry

- Absolute neutrophil count (ANC) > 750 cells/mm^3

- Hemoglobin = 9.0 g/dL

- Platelet count = 100,000/mm^3

- AST (SGOT), ALT (SGPT) = 3 times upper limit of normal (ULN)

- Total or conjugated (direct) bilirubin = 2.5 times ULN within 45 days before study entry, with the exception of isolated hyperbilirubinemia that is considered due to atazanavir

- Calculated creatinine clearance = 60 mL/min

- No hemophilia

- No active drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements

- No serious illness requiring systemic treatment and/or hospitalization within 45 days prior to entry

- No serious medical or psychiatric illness that, in the opinion of the site Investigator, will interfere with the ability of the subject to give informed consent or adhere to the protocol

- No allergy to yeast or any of the components of Gardasil

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior splenectomy

- No prior receipt of Gardasil or other HPV vaccine

- No use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG within 45 days prior to study entry

- No expected use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids used for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG during study followup

- No patients with hepatitis C who expect to initiate treatment for hepatitis C (e.g., interferons) during this trial

- Not currently receiving anticoagulation therapy other than acetylsalicylic acid

Study Design


Intervention

Biological:
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

Other:
laboratory biomarker analysis


Locations

Country Name City State
Puerto Rico University of Puerto Rico Comprehensive Cancer Center San Juan
United States University of Colorado Cancer Center at UC Health Sciences Center Aurora Colorado
United States Boston University Cancer Research Center Boston Massachusetts
United States Fenway Community Health Boston Massachusetts
United States Montefiore Medical Center Bronx New York
United States Montefiore Medical Center Bronx New York
United States John H. Stroger, Jr. Hospital of Cook County Chicago Illinois
United States Ruth M. Rothstein Core Center at Cook County Hospital Chicago Illinois
United States Dan L. Duncan Cancer Center at Baylor College of Medicine Houston Texas
United States Thomas Street Health Center Houston Texas
United States Moores UCSD Cancer Center La Jolla California
United States Childrens Hospital Los Angeles Los Angeles California
United States UCLA Clinical AIDS Research and Education (CARE) Center Los Angeles California
United States St. Jude's Children's Research Hospital Memphis Tennessee
United States Laser Surgery Care New York New York
United States Washington University School of Medicine Saint Louis Missouri
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Virginia Mason Medical Center Seattle Washington
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (6)

Lead Sponsor Collaborator
AIDS Malignancy Consortium AIDS and Cancer Specimen Resource, Merck Sharp & Dohme Corp., National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 6 positive DNA in participants without HPV-6 related AIN at baseline. Post Month 7 through Month 24
Primary Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 11 DNA Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 11 positive DNA in participants without HPV-11 related AIN at baseline. Post Month 7 through Month 24
Primary Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 16 DNA Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 16 positive DNA in participants without HPV-16 related AIN at baseline. Post Month 7 through Month 24
Primary Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 18 DNA Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 18 positive DNA in participants without HPV-18 related AIN at baseline. Post Month 7 through Month 24
Primary Incidence of Persistent Anogenital Infection With HPV 6 DNA Incident events are defined as having HPV 6 positive PCR results at 2 or more consecutive visits in those who were DNA negative for HPV 6. Persistence was defined based on being persistent in the same anatomical site. Post Month 7 through Month 24
Primary Incidence of Persistent Anogenital Infection With HPV 11 DNA Incident events are defined as having positive PCR results with HPV 11 at 2 or more consecutive visits in those who were DNA negative for HPV 11 at baseline. Persistence was defined based on being persistent in the same anatomical site. Post Month 7 through Month 24
Primary Incidence of Persistent Anogenital Infection With HPV 16 DNA Incident events are defined as having positive PCR results with HPV 16 at 2 or more consecutive visits in those who were DNA negative for HPV 16 at baseline. Persistence was defined based on being persistent in the same anatomical site. Post Month 7 through Month 24
Primary Incidence of Persistent Anogenital Infection With HPV 18 DNA Incident events are defined as having positive PCR results with HPV 18 at 2 or more consecutive visits in those who were DNA negative for HPV 18. Persistence was defined based on being persistent in the same anatomical site. Post Month 7 through Month 24
Primary Incidence of HGAIN Associated With HPV 6 Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 6 positive DNA in participants without HPV 6 related HGAIN at baseline. Post month 7 through month 24
Primary Incidence of HGAIN Associated With HPV 11 Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 11 positive DNA in participants without HPV 11 related HGAIN at baseline. Post month 7 through month 24
Primary Incidence of HGAIN Associated With HPV 16 Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 16 positive DNA in participants without HPV 16 related HGAIN at baseline. Post month 7 through month 24
Primary Incidence of HGAIN Associated With HPV 18 Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 18 positive DNA in participants without HPV 18 related HGAIN at baseline. Post month 7 through month 24
Primary Incidence of Penile/Scrotal Condyloma in HPV 6 Naive and Prior Exposed Participants Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline. Post month 7 through month 24
Primary Incidence of Penile/Scrotal Condyloma in HPV 11 Naive and Prior Exposed Participants Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline. Post month 7 through month 24
Primary Incidence of Penile/Scrotal Condyloma in HPV 16 Naive and Prior Exposed Participants Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline. Post month 7 through month 24
Primary Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline. Post month 7 through month 24
Secondary Occurrence of Grade = 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine Number of participants who experienced grade 3 and higher AEs that were possibly, probably or definitely related to the vaccine. Through Month 24
Secondary Geometric Mean Titers for HPV 6 Geometric mean concentration of antibodies for HPV 6 at each visit Baseline through month 24
Secondary Geometric Mean Titers for HPV 11 Geometric mean concentration of antibodies for HPV 11 at each visit Baseline through month 24
Secondary Geometric Mean Titers for HPV 16 Geometric mean concentration of antibodies for HPV 16 at each visit Baseline through 24 months
Secondary Geometric Mean Titers for HPV 18 Geometric mean concentration of antibodies for HPV 18 at each visit Baseline through 24 months
Secondary Geometric Mean Titers for HPV 6 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level Geometric mean concentration of antibodies for HPV 6 at 7 and 24 months at 7 and 24 Months
Secondary Geometric Mean Titers for HPV 11 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level Geometric mean concentration of antibodies for HPV 11 at 7 and 24 months at 7 and 24 Months
Secondary Geometric Mean Titers for HPV 16 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level Geometric mean concentration of antibodies for HPV 16 at 7 and 24 months at 7 and 24 Months
Secondary Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level Geometric mean concentration of antibodies for HPV 18 at 7 and 24 months at 7 and 24 Months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05060471 - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients Phase 2
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Completed NCT05518201 - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Phase 1
Withdrawn NCT02857608 - A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Phase 2
Active, not recruiting NCT02546973 - Quality of Life in Patients With Anal Cancer
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00550589 - Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Phase 2
Completed NCT00324415 - Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Phase 2
Terminated NCT00568425 - QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Terminated NCT00267787 - Molecular Genetic and Pathological Studies of Anal Tumors
Completed NCT00066430 - Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Phase 1
Completed NCT04083053 - High-Resolution Anoscopy Perceived Discomfort Study N/A
Completed NCT03506529 - Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Recruiting NCT05835947 - Anal Cancer Risk In Women
Not yet recruiting NCT03947775 - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL Phase 2
Recruiting NCT04857528 - Detecting HPV DNA in Anal and Cervical Cancers
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Active, not recruiting NCT01937780 - Anal Cancer Radiotherapy Study